News

The ‘Little Monster’ Strikes Again

Serotonin, norepinephrine, and dopamine are all chemicals involved in regulating mood, energy, motivation, appetite, and sleep. Also, the brain’s frontal lobe, which is important in controlling mood, is known to be underactive in people with Parkinson’s disease. It’s no wonder that Parkinson’s patients may look sad. We have every right. Our brain is messed up! But looking sad and feeling sad…

Continue Reading

News

One-item Scale Is Reliable Tool to Assess Fatigue in Parkinson’s Patients, Study Finds

The one-item Fatigue Visual Analog Scale (VAFS) is a highly consistent and reliable tool to assess fatigue in patients with Parkinson’s disease, and is associated with their quality of life, according to researchers. Their study, “The dimensionality of fatigue in Parkinson’s disease,” was published in the Journal of Translational Medicine. Fatigue is one of the most common, but often under-recognized,…

Continue Reading

News

Tiny Particles Prevent Neuronal Loss, Improve Motor Symptoms in Parkinson’s Mouse Study

Tiny crystals known as quantum dots can block the formation of Parkinson’s hallmark protein clumps, lowering nerve cell death and motor deficits, a mouse study has found. The research, “Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease,” was published in Nature Nanotechnology. Quantum dots are very small, engineered crystals with a diameter of as few as 10 to 100 atoms. They have electronic…

Continue Reading

News

UK Experts Outline Practical Ways to Manage Wearing-off in Parkinson’s

A panel of United Kingdom-based experts has defined a set of practical considerations to manage motor fluctuations and wearing-off in Parkinson’s disease patients. Based on practical clinical experience, the guidelines were outlined in “Noninvasive options for ‘wearing-off’ in Parkinson’s disease: a clinical consensus from a panel of UK Parkinson’s disease specialists,” published in the journal Neurodegenerative Disease Management. Currently, the…

Continue Reading

News

More Than 1 Million Cases of Parkinson’s Predicted in the US by 2030, Study Reports

Approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by the year 2030, according to the results of a large-scale study. This represents a projected increase by about 1.8 times in Parkinson’s prevalence since 2010, highlighting the need for optimized care and treatment strategies for this patient population to diminish the burden of care on caregivers and…

Continue Reading

News

Mirapex Sustained Release Tablet Outperforms Immediate Release Version to Relieve Sleep Disturbances

Sustained release formulation of pramipexole (Mirapex, Boehringer Ingelheim) outperforms its immediate release alternative to treat sleep disturbances in advanced Parkinson’s patients, a new study suggests. The research, “Comparison of nocturnal symptoms in advanced Parkinson’s disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations,” was published in Drug Design, Development and Therapy. Sleep disturbances, which may include insomnia, nightmares, restless sleep and…

Continue Reading

News

Even More Ways to #SummerOn with Parkinson’s

With Parkinson’s disease (PD), we know how challenging it can be to manage “off” times. That’s why it is important to seek out more of what helps us feel “on.” Let’s dedicate this summer to trying new things, being grateful to those around us, creating heartfelt memories and doing what makes us happy. This summer, we challenge you to try…

Continue Reading

News

‘You Don’t Look Sick’

“Invisible” disease: a disease that is not necessarily visible to the human eye; hidden; concealed from others. Parkinson’s disease (PD) can be known as an “invisible” disease. However, since PD is most commonly characterized by tremors in the extremities and shaking, most people don’t think of it as an invisible disease. But many don’t understand that some people with Parkinson’s don’t…

Continue Reading

News

3D Structure of Alpha-Synuclein Challenges Previous Theory of Parkinson’s

Researchers have analyzed the three-dimensional toxic form of the protein alpha-synuclein, which is directly involved in Parkinson’s disease. The findings are now challenging previous knowledge investigators had of this disease. Parkinson’s disease is a progressive neurodegenrative disorder that belongs to the class of synucleopathies. In these type of diseases, a protein called alpha-synuclein is abnormally high. When this protein clumps…

Continue Reading

News

PBT434 Prevents Neuron Loss, Improves Motor Function in Animal Model of Neurodegeneration, Prana Reports

Prana Biotechnology’s investigational compound PBT434 prevented neuronal loss and improved motor function in an animal model of multiple system atrophy (MSA), a condition that shares many of Parkinson’s motor symptoms, according to preclinical data. MSA is a progressive disorder affecting both involuntary functions, such as blood pressure, breathing, and digestion, and motor function, causing slow movement, rigid muscles, and poor…

Continue Reading